🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

67 results for “CORCEPT THERAPEUTICS INC” Clear

  1. An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

    CORCEPT THERAPEUTICS INC

    Endogenous Cushing Syndrome

    phase 3 other active

    1 trial

  2. Mifepristone

    CORCEPT THERAPEUTICS INC

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  3. Nab-paclitaxel 80 mg/m^2

    CORCEPT THERAPEUTICS INC

    Ovarian Neoplasm

    phase 3 small molecule active

    1 trial

  4. Relacorilant

    CORCEPT THERAPEUTICS INC

    Hypercortisolism

    phase 3 small molecule completed

    1 trial

  5. Relacorilant, 100 mg and 25 mg

    CORCEPT THERAPEUTICS INC

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule terminated

    1 trial

  6. mifepristone

    CORCEPT THERAPEUTICS INC

    Psychotic Depression

    phase 3 small molecule terminated

    1 trial

  7. mifepristone

    CORCEPT THERAPEUTICS INC

    Cushing's Syndrome

    phase 3 small molecule completed

    2 trials

  8. mifepristone

    CORCEPT THERAPEUTICS INC

    Cushing's Disease

    phase 3 small molecule terminated

    2 trials

  9. mifepristone

    CORCEPT THERAPEUTICS INC

    Major Depressive Disorder

    phase 3 small molecule completed

    5 trials

  10. relacorilant

    CORCEPT THERAPEUTICS INC

    Cushing Syndrome

    phase 3 small molecule active

    2 trials

  11. relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.

    CORCEPT THERAPEUTICS INC

    Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    phase 3 small molecule active

    1 trial

  12. CORT113176, CORT113176, Placebo to Dazucorilant softgel capsule

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  13. CORT125134

    CORCEPT THERAPEUTICS INC

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  14. CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant

    CORCEPT THERAPEUTICS INC

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

  15. Dazucorilant 300 mg

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  16. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  18. Mifepristone

    CORCEPT THERAPEUTICS INC

    Weight-Gain Prevention

    phase 2 small molecule completed

    1 trial

  19. Mifepristone

    CORCEPT THERAPEUTICS INC

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  20. Mifepristone

    CORCEPT THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  21. Mifepristone

    CORCEPT THERAPEUTICS INC

    Central Adrenal Insufficiency

    phase 2 small molecule terminated

    1 trial

  22. Mifepristone 1200 mg daily

    CORCEPT THERAPEUTICS INC

    Treatment-resistant PTSD

    phase 2 small molecule active

    1 trial

  23. Miricorilant

    CORCEPT THERAPEUTICS INC

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  24. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources